Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma.
Noguchi G, Nakaigawa N, Umemoto S, Kobayashi K, Shibata Y, Tsutsumi S, Yasui M, Ohtake S, Suzuki T, Osaka K, Muraoka K, Hasumi H, Kondo K, Igarashi Y, Sasada T, Kishida T, Yao M. Noguchi G, et al. Among authors: muraoka k. Cancer Chemother Pharmacol. 2020 Jul;86(1):75-85. doi: 10.1007/s00280-020-04088-y. Epub 2020 Jun 14. Cancer Chemother Pharmacol. 2020. PMID: 32537714
FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.
Nakaigawa N, Kondo K, Kaneta T, Tateishi U, Minamimoto R, Namura K, Ueno D, Kobayashi K, Kishida T, Ikeda I, Hasumi H, Makiyama K, Hayashi N, Osaka K, Muraoka K, Izumi K, Kawahara T, Teranishi JI, Miyoshi Y, Yumura Y, Uemura H, Inoue T, Yao M. Nakaigawa N, et al. Among authors: muraoka k. Cancer Chemother Pharmacol. 2018 Apr;81(4):739-744. doi: 10.1007/s00280-018-3542-7. Epub 2018 Feb 20. Cancer Chemother Pharmacol. 2018. PMID: 29464355
Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab.
Tabei T, Nakaigawa N, Kaneta T, Ikeda I, Kondo K, Makiyama K, Hasumi H, Hayashi N, Kawahara T, Izumi K, Osaka K, Muraoka K, Teranishi JI, Miyoshi Y, Yumura Y, Uemura H, Kobayashi K, Inoue T, Yao M. Tabei T, et al. Among authors: muraoka k. BMC Cancer. 2019 Apr 2;19(1):298. doi: 10.1186/s12885-019-5510-y. BMC Cancer. 2019. PMID: 30940117 Free PMC article. Clinical Trial.
Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma.
Jikuya R, Kishida T, Sakaguchi M, Yokose T, Yasui M, Hashizume A, Tatenuma T, Mizuno N, Muraoka K, Umemoto S, Kawai M, Yoshihara M, Nakamura Y, Miyagi Y, Sasada T. Jikuya R, et al. Among authors: muraoka k. Cancer Immunol Immunother. 2020 Oct;69(10):2041-2051. doi: 10.1007/s00262-020-02608-6. Epub 2020 May 18. Cancer Immunol Immunother. 2020. PMID: 32424467 Free PMC article.
PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer.
Kawahara T, Ishiguro Y, Ohtake S, Kato I, Ito Y, Ito H, Makiyama K, Kondo K, Miyoshi Y, Yumura Y, Hayashi N, Hasumi H, Osaka K, Muraoka K, Izumi K, Teranishi JI, Uemura H, Yao M, Nakaigawa N. Kawahara T, et al. Among authors: muraoka k. BMC Urol. 2018 Nov 6;18(1):97. doi: 10.1186/s12894-018-0414-8. BMC Urol. 2018. PMID: 30400941 Free PMC article.
Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis.
Hayashi N, Osaka K, Muraoka K, Hasumi H, Makiyama K, Kondo K, Nakaigawa N, Yao M, Mukai Y, Sugiura M, Takano S, Ito E, Kaizu H, Koike I, Hata M, Taguri M, Miyoshi Y, Izumi K, Kawahara T, Uemura H. Hayashi N, et al. Among authors: muraoka k. World J Urol. 2020 Oct;38(10):2477-2484. doi: 10.1007/s00345-019-03056-3. Epub 2019 Dec 24. World J Urol. 2020. PMID: 31875247
[A Case of Long Survival in Aggressively Growing Small Cell Carcinoma of the Bladder Successfully Treated by Combined Chemotherapy of Methotrexate, Etoposide and Cisplatin].
Jikuya R, Washimi K, Yasui M, Hashizume A, Tatenuma T, Mizuno N, Muraoka K, Umemoto S, Kawai M, Kishida T. Jikuya R, et al. Among authors: muraoka k. Hinyokika Kiyo. 2017 Jun;63(6):245-249. doi: 10.14989/ActaUrolJap_63_6_245. Hinyokika Kiyo. 2017. PMID: 28694418 Free article. Japanese.
325 results